I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in ...

India’s pharmaceutical giants are hoping to earn fat profits as their customers get thinner. With the patent for blockbuster diabetes and weight-loss drugs Ozempic and Wegovy set to expire in March, ...

Novo Nordisk announces phase 2 clinical trial results of amycretin in people with type 2 diabetes: Bagsværd, Denmark Thursday, November 27, 2025, 13:00 Hrs [IST] Novo Nordisk, a ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...